Table 4.
Name of strategy | Costs (US$) | Effectiveness (DALYs) | Incremental Costs | Incremental Effectiveness (DALY averted) | ICER (US$ / DALY averted) | Annual CC incidence per 100,000 | Remark |
---|---|---|---|---|---|---|---|
2 × screening per life time | |||||||
CS | 8.05 | 0.00429 | – | – | – | 17.06 | – |
NS alone | 12.06 | 0.00414 | 4.01 | 0.00015 | – | 16.03 | Dom |
CS + NV | 18.32 | 0.00302 | 10.27 | 0.00127 | 8087 | 11.66 | R |
NS + NV | 21.84 | 0.00293 | 3.52 | 0.00009 | 39,111 | 11.03 | NR |
3 × screening per life time | |||||||
CS | 8.07 | 0.00430 | – | – | – | 17.03 | – |
NS alone | 13.58 | 0.00413 | 5.51 | 0.00017 | – | 15.85 | Dom |
CS + NV | 18.26 | 0.00300 | 10.19 | 0.00130 | 7838 | 11.61 | R |
NS + NV | 23.31 | 0.00288 | 5.05 | 0.00012 | 42,083 | 10.80 | NR |
National screening programme achieving 40% coverage | |||||||
CS | 8.02 | 0.00427 | – | – | – | 16.95 | – |
NS alone | 13.48 | 0.00402 | 5.46 | 0.00025 | – | 15.52 | Dom |
CS + NV | 18.16 | 0.00295 | 10.14 | 0.00132 | 7682 | 11.38 | R |
NS + NV | 23.00 | 0.00280 | 4.84 | 0.00015 | 32,267 | 10.49 | NR |
National screening programme achieving 60% coverage | |||||||
CS | 7.98 | 0.00427 | – | – | – | 17.15 | – |
NS alone | 16.61 | 0.00387 | 8.63 | 0.00040 | – | 14.69 | Dom |
CS + CV | 18.26 | 0.00301 | 10.28 | 0.00126 | 8159 | 11.59 | R |
NS + NV | 25.98 | 0.00276 | 7.72 | 0.00025 | 30,880 | 10.10 | NR |
National vaccination programme achieving 90% coverage | |||||||
CS | 8.02 | 0.00429 | – | – | – | 16.90 | – |
NS alone | 10.30 | 0.00420 | 2.28 | 0.00009 | – | 16.39 | Dom |
CS + NV | 21.70 | 0.00257 | 13.68 | 0.00172 | 7953 | 9.73 | R |
NS + NV | 23.53 | 0.00253 | 1.83 | 0.00004 | 45,750 | 9.46 | NR |
National vaccination programme achieving 50% coverage | |||||||
CS | 8.00 | 0.00426 | – | – | – | 17.02 | – |
NS alone | 10.28 | 0.00417 | 2.28 | 0.00009 | – | 16.47 | Dom |
CS + NV | 15.65 | 0.00336 | 7.65 | 0.00090 | 8500 | 12.87 | R |
NS + NV | 17.67 | 0.00329 | 2.02 | 0.00007 | 28,857 | 12.48 | NR |
Cost-effectiveness threshold = US$ 9609.9/DALY averted
Gavi vaccine price ($4.5/dose) used for all analysis
CS current scenario of opportunistic screening
NS, National cervical cancer screening, NV National HPV vaccination, DALY disability adjusted life years, CC cervical cancer, R recommended, NR not recommended, Dom dominated